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Abstract
Introduction With the rapid development of mass spec-
trometry-based technologies such as multiple reaction
monitoring and heavy-isotope-labeled-peptide standards,
quantitative analysis of biomarker proteins using mass
spectrometry is rapidly progressing toward detection of
target proteins/peptides from clinical samples. Proteotypic
peptides are a few peptides that are repeatedly and
consistently identified from a protein in a mixture and are
used for quantitative analysis of the protein in a complex
biological sample by mass spectrometry.
Materials and Methods Using mass spectrometry, we
identified peptide sequences and provided a list of tryptic
peptides and glycopeptides as proteotypic peptides from
five clinically used tumor markers, including prostate-
specific antigen, carcinoembryonic antigen, Her-2, human
chorionic gonadotropin, and CA125.
Conclusion These proteotypic peptides have potential for
targeted detection as well as heavy-isotope-peptide stand-
ards for quantitative analysis of marker proteins in clinical
specimens using a highly specific, sensitive, and high-
throughout mass spectrometry-based analysis method.
Keywords Tumor marker . Cancer diagnostics .
Mass spectrometry . Proteotypic peptide . Glycopeptide
Introduction
Currently, there are 19 proteins approved by the US Food
and Drug Administration [1] as tumor markers in serum,
urine, and tissue. With the exception of prostate-specific
antigen (PSA), most of these tumor markers are intended
for monitoring response to therapy. There is an urgent need
to identify tumor markers for the detection of cancer at an
early stage when treatment is much more effective.
With the advances in proteomic technologies, protein
biomarker discovery has shown increasing promise. The
critical aspect in the development and validation of
biomarkers is to obtain precise and consistent analytical
results performed over time, with different methods, or
among different laboratories. The most popular method for
the measurement of tumor markers is immunoassay, which
provides a rapid, sensitive, and high-throughput detection
platform in the clinical setting. However, standardization is
often a challenge for tumor markers where assay compo-
nent and design including antibodies, assay parameters, and
calibration with known antigen standards are important
issues [2]. First, tumor antigen standards have to be pure
and consistent. Tumor antigens from commercial sources
are generally isolated from clinical specimens using
conventional protein purification methods, such as antibody
immunoprecipitation, electrophoresis, and chromatography.
However, they often are contaminated with other proteins
that could potentially interfere with the assays. Second,
antibodies for tumor markers need to be specific. Genera-
tion of well-defined antibodies to targeted antigens has
been a continuous and expensive effort for clinical assay
development. In addition, conditions for tumor marker
analysis need to be properly controlled. This is illustrated
by the development of appropriate reference materials for
PSA measurement [3]. Survey results among 25 methods
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for PSA determination showed 300% variability due to
different reactivities of affinity reagents in assays to the free
and complexed forms of PSA. New survey materials were
created and tested in multiple PSA assays with inter-assay
differences shown to be reduced to 15–20%. Based on
these studies, the new survey material was adopted for use
by the College of American Pathologists [3].
With the rapid development of mass spectrometry (MS)
technologies, especially with the recent introduction of
targeted analysis of proteins using multiple reaction
monitoring (MRM), sensitivity and reproducibility have
increased dramatically [4–6], increasing the potential for
MS-based methods for tumor marker detection. MRM has
several advantages over previous methods. First, the marker
proteins/peptides are identified using MS based on their
amino acid sequence. This gene-related information is
unique for each protein/peptide. Thus, the target protein/
peptide can be distinguished easily from other proteins in a
complex biological mixture. This reduces the interference
of other proteins. Second, multiple analyses can be
developed against the same proteins using different pep-
tides from the same protein, which together will produce
higher specificity and accuracy for the specific target.
Third, the sensitivity of MS detection coupling with multi-
dimensional chromatography and MRM is comparable to
that of immunoassays. The specificity of an MRM scan
greatly reduces chemical background. This enables ex-
tremely low levels of detection and limit of quantitation,
and the ability to quantify the concentration over a wider
dynamic range. Recently, it has been demonstrated that this
approach can quantify proteins in plasma at the sub-
nanogram/milliliter level with linearity over two orders of
magnitude [4]. Fourth, accurate quantification can be
achieved using MRM and heavy-isotope-labeled-peptide
standards. Unlike the traditional antigen standards for
tumor markers, the heavy-isotope-labeled-peptide standards
can be chemically synthesized using the specific amino acid
sequences from the tumor markers and specifically purified.
Their purity and content can be defined to known levels of
accuracy. Finally, the availability of highly specific anti-
bodies will no longer be an obstacle for quantitative protein
measurement using an MS-based analytical approach. The
information-dependent acquisition or monitoring of multi-
ple fragment ions from previously identified peptide stand-
ards could be used to confirm the sequences of the peptides.
Developing assays for the currently used tumor makers
using the MRM and heavy-isotope-labeled-peptide stand-
ards can provide opportunities to determine the perfor-
mance of the proteomic method by comparing MRM to the
traditional immunoassays.
Recently, the Early Detection Research Network of the
National Cancer Institute developed a reference material
based on a pooled serum standard for benchmarking serum
proteomics as a source of early cancer detection bio-
markers. This pilot reference material was spiked with
several proteins (corresponding to clinically used tumor
markers) to simulate the cancer disease state. We report
here the mass spectrometric analysis of five of the spiked
proteins—PSA, carcinoembryonic antigen (CEA), Her-2,
human chorionic gonadotropin (hCG), and CA125. The
five tumor markers were first digested using trypsin and
identified by liquid chromatography-tandem mass spec-
trometry (LC–MS/MS). In addition, N-linked glycopeptides
of each protein were isolated using solid phase extraction of
N-linked glycopeptides (SPEG) since all five tumor
markers are glycoproteins [7, 8]. The glycopeptide isolation
largely reduced the sample complexity by removing most
of the high-abundance serum peptides and significantly
improved the analytical sensitivity [7, 9]. The extracted
glycopeptides from each protein were detected by LC–MS/
MS, while the N-linked glycopeptides were identified from
the five tumor markers. Both results provided a list of
proteotypic peptides for targeted detection of these tumor
markers using MS-based methods [10]. Heavy-isotope-
labeled-peptide standards could be synthesized based upon
the peptide sequences identified here and used for the




Five tumor marker proteins were purchased from commer-
cial sources, as listed in Table 1. Sequencing grade Trypsin
Table 1 Clinically used tumor markers for mass spectrometric analysis
Protein name Molecular weight (kDa) Vendor Concentration (mg/ml) Purity (%) Purification method
PSA 30 Calbiochem 1.4 >98 Chromatography
CEA 180 Calbiochem 1.0 >98 Chromatography
Her-2 185 R&D System 1.0 >90 Unknown
hCG 36.7 Calbiochem 1.0 Unknown Precipitation
CA125 200 Cortex Unknown Unknown Unknown
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was purchased from Promega (Madison, WI), sequencing
grade endoproteinase Arg-C was from Roche (Penzberg,
Germany), peptide-N-glycosidase F (PNGase F) was from
New England BioLabs (Ipswich, MA), sodium periodate and
hydrazide resin were from Bio-Rad (Hercules, CA), C18 and
MCX desalting columns were from Waters (Milford, MS),
the nano-high-performance liquid chromatography (HPLC)
system was purchased from Eksigent (Dublin, CA, USA).
The linear trap quadrupole (LTQ) mass spectrometer was
from Thermo Fisher (Waltham, MA, USA). All trap columns
and separation columns were home packed. Other chemicals
were purchased from Sigma (St. Louis, MO, USA).
Generation of Tryptic Peptides from Clinically Used Tumor
Markers
Each tumor marker protein was digested to obtain tryptic
peptides. Proteins (10 μl from original package) were first
denatured in 45 μl of 8 M urea, 0.4 M NH4HCO3, and
0.1% sodium dodecyl sulfate for 1 h at 60°C, then reduced
by adding 5 μl of 120 mM Tris (2-carboxyethyl) phosphine
at room temperature for 30 min and alkylated by mixing
with 5 μl of 160 mM iodoacetamide at room temperature
for 30 min in the dark. Each sample was diluted with 95 μl
of trypsin digestion buffer (100 mM KH2PO4, pH 8.0) with
10 μg of trypsin, and the proteins were digested at 37°C
overnight with gentle shaking. The 0.5 ul of diluted protein
solution before adding trypsin and 0.5ul of digested
protein solution of each protein were analyzed by one
dimensional polyacrylamide gel electrophoresis (1D-
PAGE) and silver staining to monitor the protein purity
and the tryptic digestion. The digested peptides were
cleaned with C18 columns, dried, and resuspended in 10
μl of 0.4% acetic acid solution. Then, 5 μl of tryptic
peptide mixture of each protein was used in each LC–MS/
MS analysis.
N-Linked Glycopeptide Isolation
Formerly N-linked glycosylated peptides were isolated
from the tumor markers using the N-linked glycopeptide
capture procedure as described previously [8, 11]. Briefly,
10 μl of individual protein from the original source was
used for glycopeptide isolation. Five proteins were first
denatured, reduced, and alkylated using the method
described as above. Proteins, except PSA, were diluted
with 95 μl of trypsin digestion buffer and digested using 10
μg of trypsin. The PSA protein was diluted with 95 μl of
Arg-C digestion buffer (100 mM Tris–HCl, 20 mM CaCl2,
10 mM dithiothreitol, 1 mM ethylenediaminetetraacetic
acid, 40 mM methylamine, pH 7.6). One microgram of
protease Arg-C was added to the digestion buffer at 37°C
overnight with gentle shaking. After digestion of proteins to
peptides, the peptides were cleaned with C18 columns and
oxidized by adding 25 μl of 100 mM sodium periodate in
50% acetonitrile at 4°C for 1 h in the dark. After removal of
the oxidant using C18 columns, the sample was conjugated
to hydrazide resin at room temperature for 4 h in 80%



















Fig. 1 1D-PAGE gel and silver staining to verify the protein purity of
five tumor markers
Table 2 Sequences of mass spectrometric identified tryptic peptides from tumor markers
Protein name Peptide sequence Precursor mass (m/z) Precursor charge Probability
PSA LSEPAELTDAVK 637.217 +2 0.999
PSA IVGGWECEK 539.592 +2 0.857
CEA SDLVNEEATGQFR 733.777 +2 0.999
CEA CETQNPVSAR 581.609 +2 0.945
Her-2 NTDTFESMPNPEGR 806.344 +2 0.999
Her-2 CWGESSEDCQSLTR 858.355 +2 0.983
hCG VLQGVLPALPQVVCNY 886.042 +2 0.999
hCG LPGCPR 350.401 +2 0.879
CA125 NSLYVNGFTHR 654.723 +2 0.952
CA125 DSLYVNGFTQR 650.710 +2 0.836
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acetonitrile. Non-glycosylated peptides were then removed
by washing the resin three times each with 800 μl of 1.5 M
NaCl, H2O, and 100 mM of NH4HCO3. N-linked glyco-
peptides were then released from the resin by addition 1
mU of PNGase F in 100 mM of NH4HCO3 and incubated
at 37°C overnight. After the final cleanup by MCX
columns, the peptides were dried and resuspended in 10
μl of 0.4% acetic acid solution. The 5 μl of glycopeptide
mixtures were used in each LC–MS/MS analysis.
Mass Spectrometric Analysis of Peptides
The tryptic peptides and N-linked glycopeptides from
tumor markers were analyzed using an LC–MS/MS
platform. Five microliters of tryptic peptides and 5 μl of
N-linked glycopeptides were injected into an Eksigent
nano-HPLC system. Peptides were then separated by a
nano-scale C-18 reverse phase column (75-μm inner di-
ameter×10 cm long and packed with YMC ODS-AQ, 5 μm
1 PSA: LSEPAELTDAVK 2 PSA: IVGGWECEK
b+ # AA # y+ y2+
114.1674 1 L 12
201.2456 2 S 11 1160.2664 580.6372
330.3611 3 E 10 1073.1882 537.0981
427.4777 4 P 9 944.0727 472.5403
498.5565 5 A 8 846.9561 423.982
627.672 6 E 7 775.8773 388.4426
740.8315 7 L 6 646.7618 323.8849
841.9365 8 T 5 533.6023 267.3051
957.0251 9 D 4 432.4973 216.7526
1028.1039 10 A 3 317.4087 159.2083
1127.2365 11 V 2 246.3299 123.6689














































b+ # AA # y+ y2+
114.1674 1 I 9
213.2999 2 V 8 965.0167 483.0123
270.3519 3 G 7 865.8841 433.446
327.4038 4 G 6 808.8322 404.9201
513.617 5 W 5 751.7803 376.3941
642.7325 6 E 4 565.5671 283.2875
802.8713 7 C 3 436.4516 218.7298
931.9867 8 E 2 276.3128 138.6604
9 K 1 147.1973 74.1026













































3 CEA: SDLVNEEATGQFR 4 CEA: CETQNPVSAR
b+ # AA # y+ y2+
88.0861 1 S 13
203.1747 2 D 12 1379.4692 690.2386
316.3342 3 L 11 1264.3806 632.6943
415.4667 4 V 10 1151.2211 576.1145
529.5706 5 N 9 1052.0886 526.5483
658.6861 6 E 8 937.9847 469.4963
787.8015 7 E 7 808.8693 404.9386
858.8803 8 A 6 679.7538 340.3809
959.9854 9 T 5 608.675 304.8415
1017.0373 10 G 4 507.5699 254.2889
1145.1681 11 Q 3 450.518 225.763
1292.3446 12 F 2 322.3873 161.6976
13 R 1 175.2107 88.1093
200 400 600 800 1000 1200 1400
m/z
0
b+ # AA # y+ y2+
161.1467 1 C 10
290.2622 2 E 9 1002.0721 501.54
391.3673 3 T 8 872.9566 436.9823
519.498 4 Q 7 771.8515 386.4297
633.6019 5 N 6 643.7208 322.3644
730.7185 6 P 5 529.6169 265.3124
829.8511 7 V 4 432.5003 216.7541
916.9293 8 S 3 333.3677 167.1878
988.0081 9 A 2 246.2895 123.6487
10 R 1 175.2107 88.1093


































































































b+ # AA # y+ y2+
115.1118 1 N 14
216.2169 2 T 13 1497.5769 749.2924
331.3055 3 D 12 1396.4718 698.7399
432.4105 4 T 11 1281.3832 641.1956
579.5871 5 F 10 1180.2781 590.643
708.7026 6 E 9 1033.1016 517.0548
795.7808 7 S 8 903.9861 452.497
942.9734 8 M 7 816.9079 408.9579
1040.0901 9 P 6 669.7153 335.3616
1154.1939 10 N 5 572.5986 286.8033
1251.3106 11 P 4 458.4948 229.7514
1380.4261 12 E 3 361.3781 181.193
1437.478 13 G 2 232.2626 116.6353
14 R 1 175.2107 88.1093












































b+ # AA # y+ y2+
161.1467 1 C 14
347.3599 2 W 13 1555.564 778.286
404.4119 3 G 12 1369.3508 685.1794
533.5273 4 E 11 1312.2989 656.6534
620.6055 5 S 10 1183.1834 592.0957
707.6837 6 S 9 1096.1052 548.5566
836.7992 7 E 8 1009.027 505.0175
951.8878 8 D 7 879.9115 440.4597
1112.0266 9 C 6 764.8229 382.9154
1240.1573 10 Q 5 604.6841 302.846
1327.2355 11 S 4 476.5534 238.7807
1440.395 12 L 3 389.4752 195.2416
1541.5001 13 T 2 276.3158 138.6619
14 R 1 175.2107 88.1093








































Fig. 2 MS/MS spectra and fragment ion lists of selected tryptic peptides from five tumor markers
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particle size, 120A pore size) at a flow rate of 300 nl/min. The
HPLC mobile phases A and B were 0.1% formic acid in
HPLC grade water and 0.1% formic acid in 90% HPLC grade
acetonitrile, respectively. The mobile phase B was increased
from 10% to 60% in 33 min and then increased to 100% in 22
min. A 2.1-kV spray voltage was applied to transfer the
separated peptides from HPLC to a LTQ ion trap mass
spectrometer. The precursor scans from 350–1,800 m/z and
top eight ions were picked up for MS/MS scan. The resulting
MS/MS spectra were used for peptide identification.
Identification of Peptide Sequences
Peptides were identified using a database search. The MS/MS
spectra were searched against the public database (version
2.28 of the International Protein Index human protein database
containing 40,110 entries) using the Sequest [12]. The
parameters for the database search were as follows: (1) The
mass tolerance of the precursor set at ±2 m/z unit, (2)
presence of protein modifications for tryptic peptides
including carboxymethylation of cysteines and oxidation of
methionines, (3) presence of protein modifications for
glycopeptides including carboxymethylation of cysteines,
oxidation of methionines, and an enzyme-catalyzed conver-
sion of asparagine to aspartic acid at glycosylated site.
Database search results were statistically analyzed using
PeptideProphet, which effectively computes a probability
for the likelihood of each identification being correct (on a
scale of 0 to 1) in a data-dependent fashion [13]. A
minimum PeptideProphet probability score of 0.8 was used
to remove low probability peptides. For N-linked glyco-
peptides, a N-linked glycosylation consensus motif (N-X-S/
T, where X is any amino acid except proline) [14] and the
conversion of asparagine to aspartic acid were used to
identify the glycosylation sites. A maximum of two tryptic
peptides and two N-linked glycopeptides were selected
based on the rank of PeptideProphet score to represent each
tumor markers.
Results
The Purities of Tumor Marker Proteins
The five tumor marker proteins were purchased from
commercial sources. Based on the information provided by
the vendors, two proteins, PSA and CEA, were purified by
7 HCG: VLQGVLPALPQVVCNY 8 HCG: LPGCPR
b+ # AA # y+ y2+
100.1405 1 V 16
213.2999 2 L 15 1671.9433 836.4756
341.4307 3 Q 14 1558.7839 779.8959
398.4826 4 G 13 1430.6532 715.8306
497.6151 5 V 12 1373.6013 687.3046
610.7746 6 L 11 1274.4687 637.7383
707.8913 7 P 10 1161.3093 581.1586
778.9701 8 A 9 1064.1926 532.6003
892.1295 9 L 8 993.1138 497.0609
989.2462 10 P 7 879.9543 440.4811
1117.3769 11 Q 6 782.8377 391.9228
1216.5095 12 V 5 654.7069 327.8574
1315.642 13 V 4 555.5744 278.2912
1475.7808 14 C 3 456.4418 228.7249
1589.8847 15 N 2 296.303 148.6555
16 Y 1 182.1992 91.6036
400 600 800 1000 1200 1400 1600
m/z
0
b+ # AA # y+ y2+
114.1674 1 L 6
211.2841 2 P 5 586.6348 293.8214
268.336 3 G 4 489.5181 245.263
428.4748 4 C 3 432.4662 216.7371
525.5915 5 P 2 272.3274 136.6677
6 R 1 175.2107 88.1093



















































































b+ # AA # y+ y2+
115.1118 1 N 11
202.19 2 S 10 1194.3353 597.6716
315.3494 3 L 9 1107.2571 554.1325
478.5254 4 Y 8 994.0977 497.5528
577.6579 5 V 7 830.9217 415.9648
691.7618 6 N 6 731.7892 366.3986
748.8137 7 G 5 617.6853 309.3466
895.9903 8 F 4 560.6334 280.8207
997.0953 9 T 3 413.4569 207.2324
1134.2364 10 H 2 312.3518 156.6799
11 R 1 175.2107 88.1093























































































b+ # AA # y+ y2+
116.0965 1 D 11
203.1747 2 S 10 1185.325 593.1665
316.3342 3 L 9 1098.2468 549.6274
479.5101 4 Y 8 985.0873 493.0476
578.6427 5 V 7 821.9114 411.4597
692.7465 6 N 6 722.7788 361.8934
749.7985 7 G 5 608.675 304.8415
896.975 8 F 4 551.6231 276.3155
998.0801 9 T 3 404.4465 202.7272
1126.2108 10 Q 2 303.3414 152.1747
11 R 1 175.2107 88.1093
Fig. 2 (continued)
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Table 3 Mass spectrometric identified proteins and tryptic peptides from PSA antigens purchased from commercial source
No. Protein name Peptide sequence Peptide probability
1 Ig kappa chain C region DSTYSLSSTLTLSK 0.999
1 Ig kappa chain C region VDNALQSGNSQESVTEQDSK 0.987
2 Long isoform of cysteine-rich secretory protein-1 YCDMTESNPLER 0.999
2 Long isoform of cysteine-rich secretory protein-1 ATCLCDTEIK 0.907
3 Prostate-specific antigen LSEPAELTDAVK 0.999
3 Prostate-specific antigen SEPAELTDAVK 0.999
3 Prostate-specific antigen IVGGWECEK 0.857
4 Serum albumin AVMDDFAAFVEK 0.999
4 Serum albumin FSALEVDETYVPK 0.999
4 Serum albumin KVPQVSTPTLVEVSR 0.999
4 Serum albumin VPQVSTPTLVEVSR 0.999
4 Serum albumin KVPQVSTPTLVEVSR 0.999
4 Serum albumin KQTALVELVK 0.991
4 Serum albumin FQNALLVR 0.980
4 Serum albumin YICENQDSISSK 0.978
4 Serum albumin LVNEVTEFAK 0.977
4 Serum albumin CCTESLVNR 0.964
4 Serum albumin QNCELFEQLGEYK 0.961
4 Serum albumin QTALVELVK 0.961
4 Serum albumin AAFTECCQAADK 0.954
4 Serum albumin DDNPNLPR 0.890
4 Serum albumin SLHTLFGDK 0.849
4 Serum albumin AEFAEVSK 0.819
5 Lactotransferrin GEADAMSLDGGYVYTAGK 0.999
5 Lactotransferrin FFSASCVPGADK 0.947
6 Epididymal secretory protein E1 GVPVPFPIPEPDGCK 0.999
6 Epididymal secretory protein E1 SGINCPIQK 0.981
6 Epididymal secretory protein E1 DCGSVDGVIK 0.975
6 Epididymal secretory protein E1 TYSYLNK 0.917
7 Ig gamma-1 chain C region TTPPVLDSDGSFFLYSK 0.999
7 Ig gamma-1 chain C region GPSVFPLAPSSK 0.957
7 Ig gamma-1 chain C region NQVSLTCLVK 0.801
8 Prostaglandin-H2 D-isomerase TMLLQPAGSLGSY 0.999
8 Prostaglandin-H2 D-isomerase VSVQPNFQQDK 0.609
9 Isoform of proactivator polypeptide GCSFLPDPYQK 0.999
10 Haptoglobin DIAPTLTLYVGK 0.994
11 Acrosin VQPTNVCAGYPVGK 0.997
12 Serotransferrin MYLGYEYVTAIR 0.989
13 Hemopexin GGYTLVSGYPK 0.989
14 Alpha-1-antitrypsin, PRO2275 LSITGTYDLK 0.982
15 Unnamed protein VATVSLPR 0.970
16 Complement C4 VLSLAQEQVGGSPEK 0.944
Table 4 Sequences of mass spectrometric identified N-linked glycopeptides from tumor markers
Protein name Peptide sequence Precursor mass (m/z) Precursor charge Probability
PSA N*KSVILLGR 1,000.616 +1 0.998
CEA NSGLYTCQAN*NSASGHSR 642.321 +3 0.999
CEA ITPNNN*GTYACFVSNLATGR 1,086.174 +2 0.979
Her-2 ALAVLDNGDPLN*NTTPVTGASPGGLR 841.268 +3 0.999
Her-2 GPGPTQCVN*CSQFLR 861.425 +2 0.999
hCG CRPIN*ATLAVEK 687.284 +2 0.999
hCG VN*TTICAGYCPTMTR 881.464 +2 0.999
CA125 TLN*FTITNLR 597.691 +2 0.974
N* N-linked glycosylation sites and converted to D after deglycosylation
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chromatographic methods with purities higher than 98%.
hCG was precipitated from pregnant women’s urine without
additional purification. The purification methods of the other
two proteins were not provided by the vendors. Each of the
proteins was tested by 1D-PAGE gel (with 4–20% of gradient)
and silver staining to verify the protein purity (see Fig. 1). The
silver staining showed that all tumor marker proteins
purchased for this study contained other protein bands than
the expected tumor antigens. This result clearly showed that
the purification methods for these tumor antigen standards
were not sufficient to produce highly purified proteins.
Tryptic Peptide Identification
To increase the accuracy of biomarker protein detection in
clinical samples, mass spectrometry was used to identify
tryptic peptides for each tumor marker protein. All five
marker proteins were digested by trypsin, and the digested
1 PSA: N*KSVILLGR 2 CEA: NSGLYTCQAN*NSASGHSR
3 CEA: ITPNNN*GTYACFVSNLATGR 4 Her-2: ALAVLDNGDPLN*NTTPVTGASPGGLR
5 Her-2: GPGPTQCVN*CSQFLR 6 HCG: CRPIN*ATLAVEK
b+ # AA # y+ y2+
114.1674 1 I 20
215.2725 2 T 19 2058.1809 1029.5944
312.3891 3 P 18 1957.0759 979.0419
426.4930 4 N 17 1859.9592 930.4836
540.5968 5 N 16 1745.8553 873.4316
654.7007 6 N 15 1631.7515 816.3797
711.7526 7 G 14 1517.6477 759.3278
812.8577 8 T 13 1460.5957 730.8018
976.0336 9 Y 12 1359.4907 680.2493
1047.1124 10 A 11 1196.3147 598.6613
1207.2512 11 C 10 1125.2359 563.1219
1354.4278 12 F 9 965.0971 483.0525
1453.5603 13 V 8 817.9205 409.4642
1540.6385 14 S 7 718.7880 359.8980
1654.7424 15 N 6 631.7098 316.3589
1767.9018 16 L 5 517.6059 259.3069
1838.9806 17 A 4 404.4465 202.7272
1940.0857 18 T 3 333.3677 167.1878
1997.1376 19 G 2 232.2626 116.6353
20 R 1 175.2107 88.1093












































b+ b2+ # AA # y+ y2+ y3+
72.0867 36.5473 1 A 26
185.2462 93.1271 2 L 25 2451.6980 1226.3530 817.9046
256.3250 128.6665 3 A 24 2338.5386 1169.7733 780.1848
355.4575 178.2327 4 V 23 2267.4598 1134.2339 756.4919
468.6170 234.8125 5 L 22 2168.3272 1084.6676 723.4477
583.7056 292.3568 6 D 21 2055.1678 1028.0879 685.7279
697.8094 349.4087 7 N 20 1940.0792 970.5436 647.3650
754.8613 377.9346 8 G 19 1825.9753 913.4916 609.3304
869.9499 435.4789 9 D 18 1768.9234 884.9657 590.3131
967.0666 484.0373 10 P 17 1653.8348 827.4214 551.9502
1080.2261 540.6170 11 L 16 1556.7181 778.8630 519.5780
1194.3299 597.6689 12 N 15 1443.5587 722.2833 481.8582
1309.4207 655.2143 13 N 14 1329.4549 665.2314 443.8236
1410.5258 705.7669 14 T 13 1214.3641 607.6860 405.4600
1511.6309 756.3194 15 T 12 1113.2590 557.1335 371.7583
1608.7475 804.8777 16 P 11 1012.1539 506.5809 338.0566
1707.8801 854.4440 17 V 10 915.0372 458.0226 305.6844
1808.9852 904.9966 18 T 9 815.9047 408.4563 272.6402
1866.0371 933.5225 19 G 8 714.7996 357.9038 238.9385
1937.1159 969.0619 20 A 7 657.7477 329.3778 219.9212
2024.1941 1012.6010 21 S 6 586.6689 293.8384 196.2282
2121.3108 1061.1594 22 P 5 499.5907 250.2993 167.2022
2178.3627 1089.6853 23 G 4 402.4740 201.7410 134.8300
2235.4146 1118.2113 24 G 3 345.4221 173.2150 115.8126
2348.5741 1174.7910 25 L 2 288.3701 144.6890 96.7953
26 R 1 175.2107 88.1093 59.0755



















































b+ b2+ # AA # y+ y2+ y3+
115.1118 58.0599 1 N 18
202.1900 101.599 2 S 17 1810.8437 905.9258 604.2865
259.2419 130.1249 3 G 16 1723.7655 862.3867 575.2605
372.4013 186.7046 4 L 15 1666.7136 833.8608 556.2432
535.5773 268.2926 5 Y 14 1553.5541 777.2810 518.5233
636.6824 318.8452 6 T 13 1390.3782 695.6931 464.1314
796.8212 398.9146 7 C 12 1289.2731 645.1405 430.4297
924.9519 462.9799 8 Q 11 1129.1343 565.0711 377.0501
996.0307 498.5193 9 A 10 1001.0036 501.0058 334.3398
1110.1345 555.5712 10 N 9 929.9248 465.4664 310.6469
1224.2384 612.6232 11 N 8 815.8209 408.4144 272.6123
1311.3166 656.1623 12 S 7 701.7171 351.3625 234.5777
1382.3954 691.7017 13 A 6 614.6389 307.8234 205.5516
1469.4736 735.2408 14 S 5 543.5601 272.2840 181.8587
1526.5255 763.7667 15 G 4 456.4819 228.7449 152.8326
1663.6666 832.3373 16 H 3 399.4300 200.2190 133.8153
1750.7448 875.8764 17 S 2 262.2889 131.6484 88.1016
18 R 1 175.2107 88.1093 59.0755


















































b+ # AA # y+ y2+
58.0599 1 G 15
155.1765 2 P 14 1664.7907 832.8993
212.2285 3 G 13 1567.6740 784.3410
309.3451 4 P 12 1510.6221 755.8150
410.4502 5 T 11 1413.5054 707.2567
538.5809 6 Q 10 1312.4003 656.7041
698.7197 7 C 9 1184.2696 592.6388
797.8523 8 V 8 1024.1308 512.5694
911.9561 9 N 7 924.9983 463.0031
1072.0949 10 C 6 810.8944 405.9512
1159.1731 11 S 5 650.7556 325.8818
1287.3039 12 Q 4 563.6774 282.3427
1434.4804 13 F 3 435.5467 218.2773
1547.6399 14 L 2 288.3701 144.6890
15 R 1 175.2107 88.1093





























































































b+ # AA # y+ y2+
161.1467 1 C 12
317.3342 2 R 11 1213.4219 607.2149
414.4509 3 P 10 1057.2344 529.1212
527.6103 4 I 9 960.1177 480.5628
642.7011 5 N 8 846.9583 423.9831
713.7799 6 A 7 731.8675 366.4377
814.8850 7 T 6 660.7887 330.8983
928.0445 8 L 5 559.6836 280.3458
999.1233 9 A 4 446.5241 223.7660
1098.2558 10 V 3 375.4453 188.2266
1227.3713 11 E 2 276.3128 138.6604















































b+ # AA # y+
116.0348 1 N 9
244.1297 2 K 8 885.5886
331.1617 3 S 7 757.4936
430.2302 4 V 6 670.4616
543.3142 5 I 5 571.3932
656.3983 6 L 4 458.3091
769.4823 7 L 3 345.2250
826.5038 8 G 2 232.1410
9 R 1 175.1195
Fig. 3 MS/MS spectra and fragment ion lists of selected N-linked glycopeptides from five tumor markers. N* N-linked glycosylation sites and
converted to D after deglycosylation
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peptides were analyzed by LC–MS/MS and identified using
database search. The tryptic peptides for each protein are
listed in Table 2. Two peptide sequences from each protein
were selected based on peptide identification probabilities,
and their representative MS/MS spectra and fragment ions
are shown in Fig. 2.
In addition to identifying the peptides from the known
clinically used tumor markers, we also identified other
proteins from the same sample, indicating that the tumor
antigens from commercial sources are generally contami-
nated with other proteins. For example, PSA was purified
by chromatography, and the purity reported by the vendor
was to be greater than 98%. Mass spectrometry detected 15
other proteins in the solution (Table 3). These protein
contaminants (even less than 2%) might potentially inter-
fere with clinical assays when these proteins are used as
antigen standards.
Glycopeptide Identification
Since all of the tumor markers studied are glycoproteins, N-
linked glycopeptides for all five proteins were isolated
using SPEG methods [8]. We chose SPEG as the additional
peptide purification method due to the fact that (1) all five
proteins were glycoproteins, (2) glycopeptide isolation
efficiently removed most of the high-abundance serum
peptides and significantly reduced the sample complexity,
and (3) the glycopeptides were able to be concentrated
using this method, and it largely increased the chance of
peptide identification by LC–MS/MS. Based on the MS/
MS database searching results, all five proteins were
identified by at least one glycopeptides. These glycopep-
tides were listed in Table 4. We selected peptide MS/MS
spectra from each glycopeptide in order to show the
fragment ions in Fig. 3.
Discussion
In this study, we analyzed five clinically used tumor marker
proteins using mass spectrometry and identified at least two
of their tryptic peptides and N-linked glycopeptides that can
be detected by mass spectrometry as proteotypic peptides
[10]. These identified proteotypic peptides for established
clinically important serum tumor markers are identified
here as important background data required for develop-
ment of heavy-isotope-labeled-peptide standards. The MS/
MS spectra and fragment ions from this study were
presented here for selection of fragment ion transitions for
the MRM approach. For clinical quantitative analysis,
heavy peptide standards will be spiked into clinical samples
to allow the mass spectrometers to detect both native and
heavy peptide peaks for target peptides [4–6]. The native to
heavy ratio of target peptides will provide the quantitative
marker protein level in each sample. When coupled with
chromatography and the MRM detection method, MS
detection can be sensitive and quantitative for target marker
proteins for each sample. Since multiple peptides can be
monitored simultaneously, this method can be used to
detect multiple marker proteins from a single assay. It
provides an alternative approach for the clinical laboratory
to measure marker protein levels in patient specimens in a
precise, sensitive, and high-throughput way.
Using the mass spectrometry-based approach for marker
detection, the accuracy of analytical results can be high. MS
identification is a powerful method to detect specific
peptides from a complex sample mixture. It provides
significant advantages for the analysis of clinical samples
that are often complex. Compared to immunoassays, no
protein–protein interaction can adversely affect MS analy-
sis. It significantly increases the analytical accuracy and
reliability. Also, when multiple peptides are selected from
7 HCG: VN*TTICAGYCPTMTR 8 CA125: TLN*FTITNLR 
b+ # AA # y+ y2+
100.1405 1 V 15
214.2443 2 N 14 1662.7879 831.8979
315.3494 3 T 13 1548.6840 774.8460
416.4545 4 T 12 1447.5789 724.2934
529.6139 5 I 11 1346.4739 673.7409
689.7527 6 C 10 1233.3144 617.1612
760.8315 7 A 9 1073.1756 537.0918
817.8835 8 G 8 1002.0968 501.5524
981.0594 9 Y 7 945.0449 473.0264
1141.1982 10 C 6 781.8689 391.4384
1238.3149 11 P 5 621.7301 311.3690
1339.4200 12 T 4 524.6135 262.8107
1486.6126 13 M 3 423.5084 212.2582
1587.7177 14 T 2 276.3158 138.6619
15 R 1 175.2107 88.1093
400 600 800 1000 1200 1400 1600
m/z
0
b+ # AA # y+ y2+
102.1130 1 T 10
215.2725 2 L 9 1093.2704 547.1392
330.3633 3 N 8 980.1109 490.5594
477.5398 4 F 7 865.0201 433.014
578.6449 5 T 6 717.8436 359.4258
691.8043 6 I 5 616.7385 308.8732
792.9094 7 T 4 503.5791 252.2935
907.0133 8 N 3 402.474 201.741
1020.1727 9 L 2 288.3701 144.689
10 R 1 175.2107 88.1093
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one protein, the identification and quantification of these
peptides can be used to measure marker concentration.
Moreover, MS detection does not depend on the availability
of highly specific, well-characterized antibodies, which is
often the most significant technical obstacle in achieving a
precise and sensitive immunoassay.
The peptides identified in this study were based on the
widely available LTQ ion trap instrument. It has been shown
that intrinsic peptide sequence is the major factor to determine
whether a peptide from a protein can be detected by mass
spectrometry methods [10]. However, mass spectrometers
based upon different mechanisms for ionization, ion selec-
tion, ion separation, collision-induced dissociation, and
detection may affect the generation of fragment ion patterns
and peptide identification. The mass spectrometer parameter
settings may also affect the MS identification result.
Digestion of proteins with proteases is another factor that
might affect the peptide detection. For example, glycopep-
tide N*KSVILLGR (N* represents the N-linked glycosyl-
ation site) from Arg-C digestion of PSA will not be
identified by MS if trypsin was used to cleave the peptide
after K. In which case, a peptide with two amino acids
(N*K) generated from tryptic digest would be too short for
mass spectrometry detection.
Conclusion
We identified tryptic peptides and glycopeptides from five
clinically established tumor marker proteins, including PSA,
CEA, Her-2, hCG, and CA125. The identified peptide list
provided candidate peptide targets for quantitative analysis of
marker proteins in clinical specimens. Heavy-isotope-labeled
peptides can be synthesized as standards based on the
identified peptide sequences from this study for the develop-
ment of assays of these five tumor markers. In addition, these
peptides have potential utility for many laboratories for cancer
proteomics research and may provide a basis for standardiza-
tion across a broad proteomics community. This will provide
valuable information for further refinement of standard
reference materials and assays that are critically needed for
cancer biomarker discovery and validation.
We expect that by coupling MRM detection with heavy-
isotope-labeled-peptide standards, the MS-based approach
has great potential as a clinical tool for specific, precise,
and sensitive measurement of marker protein levels from a
large number of clinical specimens.
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